CD Capital

Illumax is a company that specialises in the research and development of single-serve chemiluminescence, single-serve flow fluorescence, and laboratory automation technologies. It also offers the industry an open ecological platform for chemiluminescence and flow fluorescence.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

Full-Life Technologies is a radiotherapeutics company that provides research and development, production, and commercialization of radiopharmaceuticals for cancer therapy, delivering clinical impact for patients.

HuidaGene utilizes its proprietary CRISPR-based, AI-driven HG-PRECISE platform to develop potentially curative gene therapies. The Company is advancing clinical programs, including trials of HG004 (granted ODD & RPDD by FDA) for RPE65-associated retinal disease, HG202 RNA-editing therapy for nAMD, HG204 RNA-editing therapy (granted ODD & RPDD by FDA and ODD by EMA) for MECP2 duplication syndrome, and HG302 DNA-editing therapy (granted ODD & RPDD by FDA) for DMD. The preclinical programs include HG303 DNA-editing for ALS and CRISPR RNA-editing therapy for Alzheimer’s.

Reliable Med is a medical device developer.

Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product line includes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level.

Westlake Omics focuses on applying mass spectrometry-based proteomics and other Omics technologies to address pressing clinical needs. It is committed to making breakthroughs in precision medicine and drug R&D with an unwavering focus on critical issues that impact life and health. This vision is driven by AI-empowered high-throughput proteomic analysis of minute amounts of clinical specimens and Omics technologies, supported by technological innovation and multi-modal big data. It was founded in 2020 and is based in Hangzhou, Zhejiang, China.

Wancheng Gene is a single-cell gene detection platform, which is mainly used to serve the scientific research, clinical and industrial markets with a self-developed high-throughput single-cell sequencing technology platform. The existing services of Wancheng Gene include sample preparation, database sequencing, analysis, and sample processing. They can be freely combined according to customer needs, and provide peripheral services such as sample preparation training and biometric analysis.

Fengkaili Medical Devices develops ventricular assist devices to treat patients with heart failure. They provide a plan for improving circulation that doctors can use conveniently and patients can afford. They develop therapeutic devices to improve the health of humans with an inclusive solution.

The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.

Reliable Med is a medical device developer.

SeekGene is a provider of genetic data analysis solutions focused on the development and clinical transformation of single cell sorting assays. The SeekGene operations team has many years of research and clinical service experience, focusing on the application of single-cell sequencing technology in real-world clinical research. Its self-developed high-throughput single-cell transcriptome sequencing kit achieves world-leading performance, and is flexible, simple, economical, and accurate, which can accelerate the clinical transformation of single-cell sequencing technology.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product line includes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level.

Shanghai Baixin'an Biotechnology Co., Ltd. is to develop independent innovative products in the future, continuously develop high-value minimally invasive therapeutic products, provide better medical products and technologies for medical workers and patients, and make the largest medical and health care business. s hard work.

HuidaGene utilizes its proprietary CRISPR-based, AI-driven HG-PRECISE platform to develop potentially curative gene therapies. The Company is advancing clinical programs, including trials of HG004 (granted ODD & RPDD by FDA) for RPE65-associated retinal disease, HG202 RNA-editing therapy for nAMD, HG204 RNA-editing therapy (granted ODD & RPDD by FDA and ODD by EMA) for MECP2 duplication syndrome, and HG302 DNA-editing therapy (granted ODD & RPDD by FDA) for DMD. The preclinical programs include HG303 DNA-editing for ALS and CRISPR RNA-editing therapy for Alzheimer’s.

Shanghai Baixin'an Biotechnology Co., Ltd. is to develop independent innovative products in the future, continuously develop high-value minimally invasive therapeutic products, provide better medical products and technologies for medical workers and patients, and make the largest medical and health care business. s hard work.

Xinzhi Medical is a Shanghai-based cardiovascular interventional therapy device developer.Xinzhi Medical is committed to promoting the technical innovation of cardiovascular interventional therapy and developing interventional non-implanted products in cardiovascular field continuously.

Pulse Medical is a cardiovascular interventional device research and development manufacturer dedicated to the development, production and sales of cardiovascular medical devices. Active products include: wearable ECG monitoring equipment, extracorporeal shock meter, full-body image HD detector, cardiac motion image detector and more.Guangdong Pulse Medical Technology Co., Ltd., as a manufacturer of second- and third-class medical devices in the cardiovascular medical industry, relying on the support of governments at all levels in Zhuhai and the long-term technical guidance of experts at home and abroad, we have been in the past few years. Has achieved fruitful results.

Kang Liming Bio is a biomedical technology company that specializes in the development, production and sales of tumor screening diagnostic products such as colorectal cancer fecal non-invasive screening kits.

accunome is the generation molecular diagnostic platform DXcellence12 has received the state food and drug registration certificate as the EU CE certification, and the combined detection kit for influenza A/B and respiratory syncytial virus nucleic acid has the EU CE certification.

Cellula is a medical and health company that provides IVD products. It is engaged in the field of reproductive health and provides integrated and cost-effective IVD products. They combine clinical needs to provide patients with accurate detection solutions and to provide inspectors with more convenient and technical products.

Urotronic is a medical device company that develops a drug-coated balloon device for interventional urology. The company's drug-coated balloon technology provides a minimally invasive treatment option for men suffering from urinary tract conditions. It also creates a paradigm shift from the methods currently used by urologists to treat such conditions.

Quiknos creates the ability to combine mobile Internet with medical cold chain logistics and enters the market for medical services from the space of clinical medical examination, offering medical institutions services linked to platform software and medical cold chain transportation. They use complete medical cold chain logistics and information technology to assist grassroots doctors in improving their diagnosis and treatment levels. By enabling community-based medical institutions, quick and simple checks encourage the distribution of medical resources and make medical services accessible.

Ningbo Jenscare Scientific develops solutions around structural heart disease that include the treatment of the tricuspid valve, mitral valve, aortic valve, and heart failure. The company's contact information is its physical address.

CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

12 Sigma is an innovative healthcare company with leading artificial intelligence technology and medical imaging applications. They believe the combination of medical imaging and AI will have huge potential. It has formed partnerships with General Electric to jointly develop smart diagnosis products for tumor, cardiovascular disease and CT scan, as well as with 50 top-tier hospitals in China for applied medical diagnostics,technical research and clinical trials.

Founded in 2004, Smartee is a leading provider of digital invisible orthodontic solutions in China. As of March 2022, Smartee’s 23.6 million sets of clear aligners have successfully served orthodontic consumers worldwide. Smartee is headquartered in Shanghai, China, and overseas headquarters were established in the UK in 2021. Smartee’s production and R&D base are in Jiaxing Science and Technology City. Smartee currently has over 1,700 employees including a medical team of over 380 members led by professional PhD Orthodontists working in the Smartee Invisible Orthodontic Clinical Medical Center. Our large scale automated intelligent production base in China's "Dental Valley" (Ziyang, Sichuan) serves domestic China and the global market. As one of the leading brands in China’s invisible orthodontics industry, Smartee has introduced 3D printing technology into the field of stomatology instruments production in China and for the first time realized the large-scale production of customized clear aligners. "Innovation" is in the DNA of Smartee. Smartee bracketless invisible orthodontic technology combines clinical stomatology, computer science, biomechanics, 3D printing, and polymer material science, and has achieved a total of over 500 patents since March 2022. Smartee has a database of over 520,000 orthodontic cases, which is growing at a rate of more than 100% per year. It is recognized as one of the most innovative and growing high-tech companies in the field of stomatology R&D and production in China. Smartee's efforts and contributions in promoting the development of the Chinese invisible orthodontic industry have been fully recognized and accepted by all sectors of the industry. It is a member of the 3D Printing Medical Devices Committee of the China Association for Medical Devices Industry, a member of the team that jointly drafted the Chinese oral digitalization wording standard，a standing committee member of the Chinese Stomatological Association, an executive director unit of the Shanghai Medical Instrument Trade Association, and has obtained various honorary titles such as National Hightech Enterprise and Shanghai Little Giant Enterprise. In 2015, KaVo Group, the world's leading manufacturer of dental equipment and consumables, became a shareholder of Smartee, which announced that KaVo Group had made a strategic layout for the promising field of invisible orthodontics. In 2018, Smartee began working with the world-famous University of North Carolina (UNC) School of Dentistry to jointly research and develop orthodontic clinical medicines and clear aligners related to biomechanics and medical polymer materials. In 2019, Smartee officially became a strategic cooperative partner of China Aerospace. The two would fully combine their respective technological and resource advantages and launch a series of strategic cooperations. Smartee joined hands with China Aerospace to advance the development of China's orthodontic industry. Meanwhile, Smartee worked together with the orthodontic team led by Professor Shen Gang to develop Smartee S8 S9 S10 mandibular repositioning invisible orthodontic solutions. Smartee also completed series C funding in the same year. Investors include well known domestic and foreign industry funds and investment agencies in the medical field with solid financial strength. In 2020, Smartee cooperated with the orthodontic team led by Professor Shen Gang for the second time to develop S11 alveolar orthopaedic technology, and for the third time to start the research and development of S12 invisible and fixed fusion orthodontic technology, S16 Invisible forward traction technology. In the same year, Smartee launched a series of innovative products and technology such as multi-layer sheets and S15 Smartee Hook traction technology. In 2021, Smartee continued its cooperation with Professor Shen Gang to develop S17, S18, S19, the mandibular maintenance and perioperative orthodontic solutions. In 2022, Smartee was officially authorized to use Disney and Marvel IPs for its new Smartee Teen products for children and teenagers. With the launching of Smartee Teen, Smartee has been able to provide consumers of all ages with orthodontic correction management. In March 2022, Smartee closed its series D funding round of US$ 80 million. This round of financing will continue to accelerate its expansion in the global orthodontic industry. In the future, guided by brand and driven by innovation and capital, Smartee will adhere to the medical essence of invisible orthodontics and provide safe, efficient, and comfortable invisible orthodontic products and services to global consumers and doctors, and make healthy and beautiful smiles predictable.

Kang Liming Bio is a biomedical technology company that specializes in the development, production and sales of tumor screening diagnostic products such as colorectal cancer fecal non-invasive screening kits.

Microread is a commercialization company that focuses on sequencing technology platforms for genetic detection. They refined production processes and quality verification, and they developed a series of economical test reagents for forensic, clinical, agricultural, animal husbandry, and research fields.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

Singlera Genomics is a fast growing company focusing on non-invasive genetic testing. Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.

Sino Vision is a medical device manufacturing company based in China. The company provides X-ray computed tomography equipment, sROBOT robot CT navigation system, and sAI intelligent imaging solutions. Sino Vision was established in 2012.

Quiknos creates the ability to combine mobile Internet with medical cold chain logistics and enters the market for medical services from the space of clinical medical examination, offering medical institutions services linked to platform software and medical cold chain transportation. They use complete medical cold chain logistics and information technology to assist grassroots doctors in improving their diagnosis and treatment levels. By enabling community-based medical institutions, quick and simple checks encourage the distribution of medical resources and make medical services accessible.

Percutek Therapeutics is a cardiovascular interventional device research and development manufacturer, mainly engaged in the research and development and production of cardiac and vascular related Class III minimally invasive interventional medical devices, dedicated to providing patients with safe interventional devices for cardiovascular clinical Medical solutions, etc.

Subo Medicine is a forensic and third-party medical testing service provider. Focus on providing users with judicial testing, medical testing and related services. It has four technology platforms: biochip technology platform, automated instrument technology platform, bioinformatics platform, genetic engineering technology platform, and based on professional identification methods and appraisal qualifications, it can also provide paternity test, forensic pathology identification and forensic clinical appraisal for users. And other business.

Righton is a Shanghai-based genetic engineering technology company, focusing on research and development of molecular diagnostic reagent kits.

Sino Vision is a medical device manufacturing company based in China. The company provides X-ray computed tomography equipment, sROBOT robot CT navigation system, and sAI intelligent imaging solutions. Sino Vision was established in 2012.

Med Lighter is a multi-center clinical trial collaboration platform that focuses on realizing clinical case sharing. They assist doctors in outpatient and inpatient medical record management and follow-up to improve their work.

Biomarker Technologies provide a comprehensive genomic services consisting of science and technology, and medical technology services. Founded in 2009, Biomarker is headquartered in Beijing, China. Biomarker Technologies owns a passionate and highly-skilled R&D team of over 500 members composed of highly-educated technical staff, senior engineers, bioinformaticians and experts in diverse areas including biotechnology, agriculture, medicine, and computing.

Sino Vision is a medical device manufacturing company based in China. The company provides X-ray computed tomography equipment, sROBOT robot CT navigation system, and sAI intelligent imaging solutions. Sino Vision was established in 2012.